Form 4: Syra Health Corp Director Acquires Stock Options

A Syra Health Corp director, Avutu Reddy, acquired 15,442 stock options on November 14, 2024, under the company's 2022 Omnibus Equity Incentive Plan.

Summary

• Avutu Reddy, a director at Syra Health Corp, acquired 15,442 stock options on November 14, 2024.
• The options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• 25% of the options vested immediately upon grant.
• The remaining 75% of the options will vest in 12 equal monthly installments.
• The options have an exercise price of $0.3683 per share and expire on November 14, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally positive as it aligns the director's interests with the company's performance. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a director demonstrates confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard transaction for a director of a public company, often used as part of their compensation package to align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies.
• The vesting schedule of 25% immediately and the remainder over 12 months is a typical structure.
• The 10-year expiration period is also standard for stock options.

Stakeholder Impact

• The stock option grant may have a slightly positive impact on shareholder sentiment as it indicates director confidence.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, director, Syra Health Corp, beneficial ownership